Department of Neuroscience, Biomedicine and Movement, Section of Neurosurgery, University of Verona, Verona, Italy.
Clinical Neurosurgery, University Hospital, Piazzale Stefani 1, 37121, Verona, Italy.
Neurosurg Rev. 2020 Feb;43(1):109-117. doi: 10.1007/s10143-018-1018-1. Epub 2018 Sep 5.
Meningioma arising in the inner third of the sphenoidal wing has been well recognized since the origin of neurosurgery, yet it still poses a formidable challenge for the surgeon. Treatment strategies can be optimized through a tailored approach to surgical timing and use of a non-surgical armamentarium. The aim of this study was to evaluate the long-term effect of different strategies on progression-free survival and overall survival. We examined the clinical records of brain tumor patients to assess determinants for surgery (extent of tumor removal, postoperative complications) and for progression-free survival and overall survival in relation to timing of surgery eventually followed by stereotactic radiosurgery (SRS). The records of 60 patients were retrospectively reviewed, from preoperative assessment to a median follow-up of 104 months. All were symptomatic with prevalently visual symptoms (42.2%), large tumors (median diameter 3.44 cm), extension into the cavernous sinus (38.3%), and severe vascular involvement of one or more encased or narrowed vessels (50%). Subtotal removal was achieved in 40% of cases, mainly determined by cavernous sinus and vascular involvement; neurological complications occurred in 18.3% (persistent in 6.7% due to oculomotor and vascular injury). The overall rate of symptom improvement was 32.3% at 3 months and 49.5% at 12 months. Radiological monitoring prevented clinical progression; tumor progression occurred in 11.7% of cases. There were significant differences in progression-free survival between patients with (median 46 months) and those without (median 104 months) recurrence (p = 0.002): 12.5% after total removal, 6.2% after subtotal removal and adjuvant SRS, and 28.5% after subtotal removal and observation. The related Kaplan-Meier survival curve showed no significant difference between the three strategies. Further, disease progression after recurrence was noted in 28.6% of cases, but overall survival was not influenced by either tumor recurrence or type of treatment. Treatment failure was recorded in four cases (6.7%): one perioperative death and three later on. Surgery is the mainstay for the treatment of symptomatic meningioma and to restore neurological function; however, resectability is limited by vascular and cavernous sinus involvement. Careful postoperative monitoring prevented clinical progression and adjuvant or adjunctive SRS proved effective in tumor control. A low surgical complication rate and excellent long-term outcomes were achieved with this strategy.
蝶骨翼内三分之一的脑膜瘤自神经外科诞生以来就已被充分认识,但它仍然是外科医生面临的巨大挑战。通过针对手术时机的定制方法和使用非手术手段,可以优化治疗策略。本研究旨在评估不同策略对无进展生存期和总生存期的长期影响。我们检查了脑瘤患者的临床记录,以评估手术的决定因素(肿瘤切除程度、术后并发症)以及与手术时机相关的无进展生存期和总生存期,最终采用立体定向放射外科(SRS)治疗。回顾性分析了 60 例患者的临床记录,从术前评估到中位随访 104 个月。所有患者均有症状,主要为视觉症状(42.2%)、大肿瘤(直径中位数为 3.44cm)、向海绵窦扩展(38.3%)和一条或多条包裹或变窄血管严重受累(50%)。40%的病例达到次全切除,主要由海绵窦和血管受累决定;18.3%的患者发生神经系统并发症(由于动眼神经和血管损伤,持续存在的并发症为 6.7%)。术后 3 个月和 12 个月,症状改善的总体比例分别为 32.3%和 49.5%。影像学监测可防止疾病进展;11.7%的病例出现肿瘤进展。有复发(中位时间 46 个月)和无复发(中位时间 104 个月)的患者在无进展生存期上有显著差异(p=0.002):全切除后 12.5%,次全切除后加 SRS 为 6.2%,次全切除后观察为 28.5%。相关的 Kaplan-Meier 生存曲线显示三种策略之间无显著差异。进一步发现,复发后疾病进展占 28.6%,但肿瘤复发和治疗类型均不影响总生存期。4 例(6.7%)记录治疗失败:1 例围手术期死亡,3 例后期死亡。手术是治疗有症状脑膜瘤和恢复神经功能的主要方法;然而,由于血管和海绵窦受累,可切除性受到限制。术后仔细监测可防止临床进展,辅助或辅助 SRS 可有效控制肿瘤。该策略实现了低手术并发症率和良好的长期结果。